Ramipril, a prodrug of ramiprilat, competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation thus producing a hypotensive effect and a beneficial effect in CHF.
(in Tablet form)
Adult: Initially, 2.5 mg once daily, 1st dose preferably given at bedtime. Maintenance: 2.5-5 mg daily as a single dose, up to 10 mg/day as needed.
Adult: Initially, 1.25 mg once daily. Max: 10 mg/day. Doses ?2.5 mg may be given in single or 2 divided doses.
Adult: Initially, 2.5 mg bid, may increase to 5 mg bid after 2 days. Start treatment: 3-10 days after infarction. Maintenance: 2.5-5 mg bid.
Prophylaxis of cardiovascular events in high-risk patients:
Adult: Initially, 2.5 mg once daily, may increase to 5 mg once daily after 1 wk if tolerated. Maintenance: 10 mg once daily after a further 3 wk.
Manufacturer: Square Pharmaceutical Ltd.